Pharmaceutical company Therapix Biosciences Ltd (Nasdaq:TRPX) on Friday disclosed that it recorded a net loss USD2.14m for the first quarter of 2019.
The company recorded research and development expenses, net of USD245,000 for the three months ended 31 March 2019.
Other expenses (income), net of USD1.05m was reported for the first quarter of 2019.
In addition, the company announced cash and cash equivalents of USD2.57m, total assets of USD4.57m and total liabilities of USD5.42m, respectively, for the first quarter of 2019.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva